YTB323, TISAGENLECLEUCEL, PHE885
CCTL019A2205B
Phase 3 small_molecule active
Quick answer
YTB323, TISAGENLECLEUCEL, PHE885 for All patients who have been treated with Novartis or Penn CAR T-cell therapy for any indication is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- All patients who have been treated with Novartis or Penn CAR T-cell therapy for any indication
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active